Superworth

Corbus Pharmaceuticals EPS CRBP

Diluted earnings per share by quarter and over the last twelve months, from 2013.

Last 12 months, to Jun 30, 2026
−$6.19
Latest quarter, Q2 FY26
−$1.81
Fiscal year 2025
−$5.98

Corbus Pharmaceuticals' earnings per share was −$6.19 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.81.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$5.98n/a
FY2024−$3.66n/a
FY2023−$10.37n/a
FY2022−$10.16n/a
FY2021−$11.70n/a
FY2020−$44.40n/a
FY2019−$33.90n/a
FY2018−$29.40n/a
FY2017−$19.50n/a
FY2016−$14.40n/a
FY2015−$8.70n/a
FY2014−$3.60n/a
FY2013n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.81n/a−$6.19
Q1 FY26−$1.23n/a−$5.82
Q4 FY25−$1.25n/a−$5.98
Q3 FY25−$1.90n/a−$5.51
Q2 FY25−$1.44n/a−$4.76
Q1 FY25−$1.39n/a−$4.22
Q4 FY24−$0.78n/a−$3.66
Q3 FY24−$1.15n/a−$4.69
Q2 FY24−$0.90n/a−$5.81
Q1 FY24−$0.83n/a−$6.96
Q4 FY23−$1.81n/a−$10.37
Q3 FY23−$2.27n/a−$11.17

Against its peers

Companies in Drug Manufacturers - General nearest Corbus Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CRBPCorbus Pharmaceuticals−$6.19
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Corbus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.